Blog
New
Companion Diagnostics: Why Assay Design Decisions Can Make or Break Clinical Trials
Companion Diagnostics: Why Assay Design Decisions Can Make or Break Clinical Trials
Rita Bhui
6 Min Read
Share
Why Patient Selection Matters
Imagine a promising new targeted therapy entering a clinical trial.
The drug works but only for patients carrying specific genetic biomarkers. The challenge is identifying those patients accurately.
This is the role of companion diagnostics (CDx). A companion diagnostic determines who is likely to benefit from a therapy and who is not.
If the test misses eligible patients or incorrectly identifies ineligible ones, the trial outcomes can be affected. Even an effective drug may appear unsuccessful if the wrong patients are enrolled.
In precision medicine, the quality of the assay is just as important as the quality of the drug.
How Companion Diagnostics Are Built Today
Most CDxs are developed by measuring one or a small number of biomarkers using separate assays or limited multiplex panels.
This approach works well when:
Only a few biomarkers need to be tested
Biomarkers are well established
Clinical studies are relatively small
However, modern clinical trials are becoming far more complex.
Many therapies now depend on multiple genes, mutations, or molecular signatures rather than a single biomarker.
The Growing Complexity of Biomarker Testing
As biomarker panels grow, so do the challenges.
Adding more targets often means:
More assay optimisation
More validation studies
More reagents and testing
Higher costs and longer development timelines
At the same time, biomarkers may be present at very low levels or exist alongside highly similar genetic changes, making accurate detection difficult.
Assays must also produce consistent results across different laboratories, instruments, and patient populations. Small differences in performance can affect patient selection and ultimately influence trial outcomes.
The challenge is no longer simply detecting biomarkers; it is detecting many biomarkers accurately, efficiently, and consistently.
How AlgoBio Rethinks Assay Design
AlgoBio approaches companion diagnostics differently.
Instead of treating every biomarker as a separate measurement, AlgoBio uses computationally designed multiplex assays that analyse many targets within a single framework.
This enables:
Broader biomarker panels without proportionally increasing assay complexity
High-confidence detection by improving discrimination between true signals and background noise
Simplified validation through a unified assay design
Scalable testing for larger and more complex clinical trials
By combining molecular biology with computational design, AlgoBio helps make companion diagnostics more efficient and reliable.
Preparing Companion Diagnostics for the Future
As precision medicine continues to evolve, companion diagnostics will need to identify more biomarkers across larger and more diverse patient populations.
The future of clinical trials will depend not only on better therapies, but also on smarter assays that can reliably identify the right patients.
With computationally designed multiplex assays, AlgoBio is helping build companion diagnostics that are ready for the next generation of precision medicine.
Why Patient Selection Matters
Imagine a promising new targeted therapy entering a clinical trial.
The drug works but only for patients carrying specific genetic biomarkers. The challenge is identifying those patients accurately.
This is the role of companion diagnostics (CDx). A companion diagnostic determines who is likely to benefit from a therapy and who is not.
If the test misses eligible patients or incorrectly identifies ineligible ones, the trial outcomes can be affected. Even an effective drug may appear unsuccessful if the wrong patients are enrolled.
In precision medicine, the quality of the assay is just as important as the quality of the drug.
How Companion Diagnostics Are Built Today
Most CDxs are developed by measuring one or a small number of biomarkers using separate assays or limited multiplex panels.
This approach works well when:
Only a few biomarkers need to be tested
Biomarkers are well established
Clinical studies are relatively small
However, modern clinical trials are becoming far more complex.
Many therapies now depend on multiple genes, mutations, or molecular signatures rather than a single biomarker.
The Growing Complexity of Biomarker Testing
As biomarker panels grow, so do the challenges.
Adding more targets often means:
More assay optimisation
More validation studies
More reagents and testing
Higher costs and longer development timelines
At the same time, biomarkers may be present at very low levels or exist alongside highly similar genetic changes, making accurate detection difficult.
Assays must also produce consistent results across different laboratories, instruments, and patient populations. Small differences in performance can affect patient selection and ultimately influence trial outcomes.
The challenge is no longer simply detecting biomarkers; it is detecting many biomarkers accurately, efficiently, and consistently.
How AlgoBio Rethinks Assay Design
AlgoBio approaches companion diagnostics differently.
Instead of treating every biomarker as a separate measurement, AlgoBio uses computationally designed multiplex assays that analyse many targets within a single framework.
This enables:
Broader biomarker panels without proportionally increasing assay complexity
High-confidence detection by improving discrimination between true signals and background noise
Simplified validation through a unified assay design
Scalable testing for larger and more complex clinical trials
By combining molecular biology with computational design, AlgoBio helps make companion diagnostics more efficient and reliable.
Preparing Companion Diagnostics for the Future
As precision medicine continues to evolve, companion diagnostics will need to identify more biomarkers across larger and more diverse patient populations.
The future of clinical trials will depend not only on better therapies, but also on smarter assays that can reliably identify the right patients.
With computationally designed multiplex assays, AlgoBio is helping build companion diagnostics that are ready for the next generation of precision medicine.
Why Patient Selection Matters
Imagine a promising new targeted therapy entering a clinical trial.
The drug works but only for patients carrying specific genetic biomarkers. The challenge is identifying those patients accurately.
This is the role of companion diagnostics (CDx). A companion diagnostic determines who is likely to benefit from a therapy and who is not.
If the test misses eligible patients or incorrectly identifies ineligible ones, the trial outcomes can be affected. Even an effective drug may appear unsuccessful if the wrong patients are enrolled.
In precision medicine, the quality of the assay is just as important as the quality of the drug.
How Companion Diagnostics Are Built Today
Most CDxs are developed by measuring one or a small number of biomarkers using separate assays or limited multiplex panels.
This approach works well when:
Only a few biomarkers need to be tested
Biomarkers are well established
Clinical studies are relatively small
However, modern clinical trials are becoming far more complex.
Many therapies now depend on multiple genes, mutations, or molecular signatures rather than a single biomarker.
The Growing Complexity of Biomarker Testing
As biomarker panels grow, so do the challenges.
Adding more targets often means:
More assay optimisation
More validation studies
More reagents and testing
Higher costs and longer development timelines
At the same time, biomarkers may be present at very low levels or exist alongside highly similar genetic changes, making accurate detection difficult.
Assays must also produce consistent results across different laboratories, instruments, and patient populations. Small differences in performance can affect patient selection and ultimately influence trial outcomes.
The challenge is no longer simply detecting biomarkers; it is detecting many biomarkers accurately, efficiently, and consistently.
How AlgoBio Rethinks Assay Design
AlgoBio approaches companion diagnostics differently.
Instead of treating every biomarker as a separate measurement, AlgoBio uses computationally designed multiplex assays that analyse many targets within a single framework.
This enables:
Broader biomarker panels without proportionally increasing assay complexity
High-confidence detection by improving discrimination between true signals and background noise
Simplified validation through a unified assay design
Scalable testing for larger and more complex clinical trials
By combining molecular biology with computational design, AlgoBio helps make companion diagnostics more efficient and reliable.
Preparing Companion Diagnostics for the Future
As precision medicine continues to evolve, companion diagnostics will need to identify more biomarkers across larger and more diverse patient populations.
The future of clinical trials will depend not only on better therapies, but also on smarter assays that can reliably identify the right patients.
With computationally designed multiplex assays, AlgoBio is helping build companion diagnostics that are ready for the next generation of precision medicine.